Studies have shown that the NF-κB pathway is constitutively activated and upregulated in glioma cells in response to different stimuli, since a negative feedback loop exists in the regulation of NF-κB, in which the key intermediate protein that determines the activation degree of NF-κB was found to be TNF receptor associated factor 3 (TRAF3) and the upstream regulator is RIPK2. Here, RIPK2 is linked to central nervous system cancer.